| Literature DB >> 19521755 |
Randy Manusama1, Carl Timmermans, Laurent Pison, Suzanne Philippens, David Perez, Luz-Maria Rodriguez.
Abstract
PURPOSE: Catheter-based cryoablation (cryo) has proven to be as effective as radiofrequency energy (RF) ablation for the treatment of arrhythmias. Nevertheless, the duration of cryoapplications has been reported as being significantly longer than RF applications.Entities:
Mesh:
Year: 2009 PMID: 19521755 PMCID: PMC2746293 DOI: 10.1007/s10840-009-9405-8
Source DB: PubMed Journal: J Interv Card Electrophysiol ISSN: 1383-875X Impact factor: 1.900
Demographics
| Patients | 37 |
| Age, years | 59 ± 14 |
| Sex, M/F | 28/9 |
| Structural heart disease, n | 24 |
| Hypertensive | 10 |
| Ischemic | 4 |
| Dilated | 3 |
| Valvular | 1 |
| Hypertensive/ischemic | 3 |
| Hypertensive/Dilated | 2 |
| Hypertensive/Valvular | 1 |
| Mean left ventricular ejection fraction ,% | 54 ± 15 |
| Mean left atrial size, mm | 45 ± 7 |
| Concomitant atrial fibrillation, n | 24 |
| Pacemaker/ICD, n | 4/2 |
| IC AFL, n | 4 |
| Class III AAD (amiodaron/sotalol/both), n | 6/10/1 |
| Other AAD, n | 16 |
n number of patients; AAD anti-arrhythmic drugs; IC AFL organisation of atrial fibrillation to atrial flutter during; treatment with IC anti-arrhythmic drugs; ICD intracardiac defibrillator
Electrophysiological characteristics of the index-procedure
| AFL, CCW/CW | 34/3 |
| Cycle length, ms | 252 ± 44 |
| Patients requiring cardioversion, | 8 |
| Chemical, and | 3 |
| Electrical | 8 |
| Successful 1-min-application, n | 31/36 (86%) |
| Number of 1-min-applications | 7 ± 2 |
| Temperature, °C | −88 ± 2 |
| Fluoroscopy time, min | 27 ± 14 |
| Procedure time, min | 110 ± 28 |
| Acute success, n | 35/36 (97%) |
| Recurrence AFL, n | 2/36 (6%) |
AFL atrial flutter; CCW counterclockwise; CW clockwise; n number of patients
Baseline characteristics of CTI conduction properties
| Repeat EPS | No Repeat EPS | ||
|---|---|---|---|
| CTI block | CTI conduction | Undetermined | |
| Patients | 12 | 12 | 12 |
| Age, years | 56 ± 18 (18–78) | 63 ± 10 (51–77) | 57 ± 12 (25–71) |
| Concomitant AF, n | 7 | 10 | 7 |
| LA size, mm | 45 ± 10 (29–63) | 43 ± 3 (38–47) | 46 ± 9 (30–58) |
| AFL, CCW/CW | 10/2 | 12/0 | 11/1 |
| AFL cycle length, ms | 261 ± 54 (190–328) | 251 ± 59 (180–360) | 245 ± 30 (200–300) |
| Total number of successful 1-min | |||
| cryoapplications | 6 ± 2 (3–8)*,** | 8 ± 2 (5–12) | 8 ± 4 (4–12) |
| Additional 3-min applications, n | 0** | 0 | 5 |
| Reconduction during isoprotenerol, n | 6** | 2 | 1 |
| Temperature, ºC | −86 ± 2 (−81–−90) | −87 ± 3 (−83–−94) | −87 ± 1 (−85–−88) |
| Fluoroscopy time, min | 21 ± 12 (8–54)*,** | 26 ± 6 (16–43) | 39 ± 20 (11–78) |
| Procedure time, min | 99 ± 22 (67–134) | 110 ± 24 (73–145) | 119 ± 42 (61–180) |
| Acute success, n (%) | 12 (100) | 12 (100) | 11 (92) |
| Recurrence AFL, n (%) | 0** | 2 (17) | 0 |
| Follow-up, months | 38 ± 4 (30–41) | 38 ± 5 (31–47) | 36 ± 4 (30–41) |
EPS electrophysiological study; AF atrial fibrillation; n number of patients; LA left atrium; AFL atrial flutter; CCW counterclockwise; CW clockwise
*P < 0.05 compared to patients with CTI conduction, **P < 0.05 compared to patients with or undetermined CTI conduction
Electrophysiological and ablation characteristics of patients with CTI conduction recovery
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Index procedure | ||||||||||||
| Pre-ablation AAD | amio | flec | amio | BB | flec | dys | sot | amio | sot | flec | sot | sot |
| LA size, mm | 43 | 42 | 41 | 46 | 38 | 41 | 45 | 43 | 42 | 47 | 41 | 42 |
| Concomitant arrhythmias | AT | AF | AF/VT | AF | AF | AF | AF | AF | AF | CMT/AT | AF | AF |
| AFL, CCW/CW | CCW | CCW | CCW | CCW | CCW | CCW | CCW | CCW | CCW | CCW | CCW | CCW |
| Cycle length, ms | 266 | 240 | 320 | 220 | 300 | 240 | 220 | 220 | 200 | 360 | 220 | 180 |
| Conduction recovery during isoprenaline | no | yes | –a | yes | no | no | no | no | no | no | no | no |
| Successful 1-min-applications | 9 | 6 | 12 | 4 | 8 | 7 | 11 | 5 | 9 | 7 | 9 | 8 |
| Additional applications 1-min/3-min | – | 2/0 | – | 3/0 | – | – | – | – | – | – | – | – |
| Repeat procedure | ||||||||||||
| Recurrence AFL | yes | no | no | no | yes | no | no | no | no | no | no | no |
| Pre-ablation AAD | sot | flec | amio | BB | flec | dys | sot | none | sot | flec | sot | sot |
| AFL induction | no | no | yes | no | no | no | no | no | no | no | yes | no |
| Location terminal applications/gaps | AV | VC | AV | AV | VC | AV | VC | VC | AV | AV | A | AV |
| Conduction recovery during isoprenaline | no | no | –a | no | no | no | no | no | no | no | no | no |
| Successful 1-min-applications | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
See text for more details
ano isoprenaline infusion, because of repeated bouts of atrial fibrillation during atrial pacing
AAD anti-arrhythmic drugs; amio amiodarone; flec flecainide; BB beta-blocker; dys dysopyramide; sot sotalol; LA left atrium; AFL atrial flutter; CMT circus movement tachycardia; AT atrial tachycardia; CCW counter-clock wise; CW clockwise; AV atrioventricular groove; A atrial tissue between the atrioventricular groove and inferior caval vein, VC atrium-inferior caval vein transition